Cercano Management’s Denali Therapeutics DNLI Stock Holding History

Cercano Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12M	Hold	625,000	–	–	0.52%	43
2025 Q4	$10.3M	Hold	625,000	–	–	0.39%	52
2025 Q3	$9.07M	Hold	625,000	–	–	0.35%	53
2025 Q2	$8.74M	Hold	625,000	–	–	0.25%	65
2025 Q1	$8.5M	Hold	625,000	–	–	0.25%	59
2024 Q4	$12.7M	Hold	625,000	–	–	0.32%	60
2024 Q3	$18.2M	Hold	625,000	–	–	0.44%	55
2024 Q2	$14.5M	Hold	625,000	–	–	0.39%	54
2024 Q1	$12.8M	Hold	625,000	–	–	0.36%	59
2023 Q4	$13.4M	Hold	625,000	–	–	0.44%	56
2023 Q3	$12.9M	Hold	625,000	–	–	0.46%	55
2023 Q2	$18.4M	Hold	625,000	–	–	0.64%	39
2023 Q1	$14.4M	Hold	625,000	–	–	0.58%	39
2022 Q4	$17.4M	Buy	+625,000	New	+$18.6M	0.71%	36

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cercano Management's DNLI Position: Q1 2026 in Review

Cercano Management held its Denali Therapeutics (DNLI) position steady in Q1 2026 at 625,000 shares worth $12M. The position accounts for 0.52% of the portfolio, ranked #43.

Cercano Management first reported a position in DNLI in Q4 2022 and has held it in 14 quarters since. The position peaked at $18.4M in Q2 2023. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Cercano Management held 625,000 shares of Denali Therapeutics worth $12M as of Q1 2026.
Cercano Management left its Denali Therapeutics share count unchanged in Q1 2026.
Denali Therapeutics made up 0.52% of Cercano Management's portfolio in Q1 2026, its #43 holding.
Cercano Management first reported a position in Denali Therapeutics in Q4 2022 and has held it in 14 quarters since.
Cercano Management's Denali Therapeutics position peaked at $18.4M in Q2 2023.
268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Cercano Management's 13F filing for Q1 2026, filed 13 May 2026.